Lumida
/UTMD
⌘K
Utah Medical Products Inc

Utah Medical Products Inc

UTMD
$69.71USD+0.10%+0.07 today

MARKET CAP

221.9M

P/E (TTM)

20.6x

FWD P/E

DAY RANGE

$69 – $70

52W RANGE

$54
$76

AI Summary

Stalk
Sell NowHigh

UTMD’s price has dipped below the 9EMA, 20EMA, and 50DMA with an active Lower Highs & Lower Lows pattern indicating supply dominance and downward momentum. In a Stage 4 decline with neutral OB/OS, the medium-term posture remains bearish. Short-term timing conditions align with further downside as price tightly tracks below sloping EMAs. Execution is now appropriate on rallies into the broken EMA cluster. Only a sustained reclaim above these EMAs and recent resistance zone would invalidate this stance.

  • Earnings Yield 36.7% and Dividend Yield 1.8% support income investors.
  • Q2 revenue fell 14.3% to $8.53M while gross margin stayed 55.8%.
  • 2026 sales forecast cut 10–13% after customer losses
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$49.1M$52.3M$50.2M$40.9M$38.5M
YoY %+16.3%+6.6%-3.9%-18.6%-5.8%
P / Sales7.5x6.8x6.0x5.3x4.7x
EV / Sales6.4x5.6x4.3x3.4x2.6x
Gross Profit, Adj.$30.9M$32.2M$30.0M$24.1M$22.0M
YoY %+21.0%+4.1%-6.7%-19.6%-8.9%
Margin %63.0%61.6%59.8%59.0%57.1%
EV / Gross Profit10.1x9.0x7.3x5.7x4.5x
EBITDA, Adj.$26.2M$26.8M$23.1M$16.4M$14.4M
YoY %+25.1%+2.5%-13.9%-29.0%-12.4%
Margin %53.3%51.3%46.0%40.1%37.3%
EV / EBITDA12.0x10.8x9.4x8.4x6.9x
EBIT$18.9M$19.8M$16.8M$13.6M$11.4M
YoY %+37.7%+4.8%-15.2%-19.0%-16.1%
Margin %38.5%37.9%33.4%33.2%29.6%
EV / EBIT16.6x14.7x13.0x10.1x8.7x
Net Income$14.8M$16.5M$16.6M$13.9M$11.3M
YoY %+37.0%+11.4%+1.0%-16.6%-18.7%
Net Margin30.1%31.5%33.1%33.9%29.3%
EPS (GAAP)$4.04$4.52$4.57$3.96$3.48
YoY %+37.4%+11.9%+1.1%-13.3%-12.1%